

GLAXOSMITHKLINE PLC
Form 6-K
October 16, 2018

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934

For period ending 16 October 2018

GlaxoSmithKline plc
(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive offices)

Indicate by check mark whether the registrant files or
will file annual reports under cover Form 20-F or Form 40-F

Form 20-F Form 40-F

--

Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.

Yes No

GlaxoSmithKline plc (the 'Company')

Transaction notification

1. Details of PDMR/person closely associated with them ('PCA')
 - a) Name Ms E N Walmsley
 - b) Position/status Chief Executive Officer
 - c) Initial notification/ amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 - a) Name GlaxoSmithKline plc
 - b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

- a) Description of the financial instrument

Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882

- b) Nature of the transaction

Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 11 October 2018.	
--	--
- c) Price(s) and volume(s)

Price(s)	Volume(s)
£14.5879	1588.542
n/a (single transaction)	

- d) Aggregated information

Aggregated volume	Price
-------------------	-------

- e) Date of the transaction 2018-10-12
- f) Place of the transaction London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')
 - a) Name Mr R G Connor
 - b) Position/status President, Global Vaccines
 - c) Initial notification/ amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

- a) Name GlaxoSmithKline plc
- b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

- a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882

- b) Nature of the transaction Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 11 October 2018.

- c) Price(s) and volume(s)

Price(s)	Volume(s)
£14.5879	43.780
n/a (single transaction)	

Aggregated information

- d) Aggregated volume Price

- e) Date of the transaction 2018-10-12
- f) Place of the transaction London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')

- a) Name Mr S P Dingemans
- b) Position/status Chief Financial Officer
- c) Initial notification/ amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

- a) Name GlaxoSmithKline plc
- b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

- a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882

- b) Nature of the transaction Acquisition of Ordinary Shares following the re-investment of dividends

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

paid to shareholders on 11
October 2018.

c) Price(s) and volume(s) Price(s) Volume(s)
£14.5879 1086.771
n/a (single transaction)

Aggregated information

d) Aggregated volume Price

e) Date of the transaction 2018-10-12
f) Place of the transaction London Stock Exchange
(XLON)

1. Details of PDMR/person closely associated with them ('PCA')

a) Name Mr J Ford
b) Position/status SVP & General Counsel
c) Initial notification/
amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor

a) Name GlaxoSmithKline plc
b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type
of instrument; (ii) each type of transaction; (iii) each date; and (iv)
each place where transaction(s) has been conducted

 Ordinary shares of 25 pence
each ('Ordinary Shares')
a) Description of the financial instrument ISIN: GB0009252882

b) Nature of the transaction Acquisition of Ordinary
Shares following the
re-investment of dividends
paid to shareholders on 11
October 2018.

c) Price(s) and volume(s) Price(s) Volume(s)
£14.5879 0.013
n/a (single transaction)

Aggregated information

d) Aggregated volume Price

e) Date of the transaction 2018-10-12
f) Place of the transaction

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

London Stock Exchange
(XLON)

1. Details of PDMR/person closely associated with them ('PCA')
 - a) Name Mr J Ford
 - b) Position/status SVP & General Counsel
 - c) Initial notification/
amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 - a) Name GlaxoSmithKline plc
 - b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 - a) Description of the financial instrument American Depository Shares ('ADSs')
ISIN: US37733W1053
 - b) Nature of the transaction Acquisition of ADSs following the re-investment of dividends paid to shareholders on 11 October 2018.
 - c) Price(s) and volume(s)

Price(s)	Volume(s)
\$38.2449	78.799
n/a (single transaction)	
 - d) Aggregated information
Aggregated volume Price
 - e) Date of the transaction 2018-10-12
 - f) Place of the transaction New York Stock Exchange (XNYS)

1. Details of PDMR/person closely associated with them ('PCA')
 - a) Name Mr N Hirons
 - b) Position/status SVP, Global Ethics & Compliance
 - c) Initial notification/
amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

- a) Name GlaxoSmithKline plc
 b) LEI 5493000HZTVUYLO1D793
 Details of the transaction(s): section to be repeated for (i) each type
 3. of instrument; (ii) each type of transaction; (iii) each date; and (iv)
 each place where transaction(s) has been conducted

Ordinary shares of 25 pence
 each ('Ordinary Shares')

- a) Description of the financial instrument ISIN: GB0009252882

- b) Nature of the transaction Acquisition of Ordinary
 Shares following the
 re-investment of dividends
 paid to shareholders on 11
 October 2018.

- c) Price(s) and volume(s)
 Price(s) Volume(s)
 £14.5879 320.252
 n/a (single transaction)

Aggregated information

- d) Aggregated volume Price

- e) Date of the transaction 2018-10-12
 f) Place of the transaction London Stock Exchange
 (XLON)

1. Details of PDMR/person closely associated with them ('PCA')

- a) Name Mr N Hirons
 SVP, Global Ethics &
 b) Position/status Compliance

- c) Initial notification/
 amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction
 platform, auctioneer or auction monitor

- a) Name GlaxoSmithKline plc
 b) LEI 5493000HZTVUYLO1D793

- Details of the transaction(s): section to be repeated for (i) each type
 3. of instrument; (ii) each type of transaction; (iii) each date; and (iv)
 each place where transaction(s) has been conducted

American Depositary Shares
 ('ADSs')

- a) Description of the financial instrument ISIN: US37733W1053

- b) Nature of the transaction

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

Acquisition of ADSs
following the re-investment
of dividends paid to
shareholders on 11 October
2018

c) Price(s) and volume(s)
Price(s) Volume(s)
\$38.2449 19.611
n/a (single transaction)

Aggregated information

d) Aggregated volume Price

e) Date of the transaction 2018-10-12
f) Place of the transaction New York Stock Exchange
(XNYS)

1. Details of PDMR/person closely associated with them ('PCA')

a) Name Mr B McNamara
CEO, GSK Consumer
b) Position/status Healthcare

c) Initial notification/
amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor

a) Name GlaxoSmithKline plc
b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type
of instrument; (ii) each type of transaction; (iii) each date; and (iv)
each place where transaction(s) has been conducted

a) Description of the financial instrument American Depositary Shares
(‘ADSs’)
ISIN: US37733W1053

b) Nature of the transaction Acquisition of ADSs
following the re-investment
of dividends paid to
shareholders on 11 October
2018

c) Price(s) and volume(s)
Price(s) Volume(s)
\$38.2449 470.948
n/a (single transaction)

Aggregated information

d) Aggregated volume Price

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

- e) Date of the transaction 2018-10-12
- f) Place of the transaction New York Stock Exchange (XNYS)

- 1. Details of PDMR/person closely associated with them ('PCA')
 - a) Name Mr D Redfern
 - b) Position/status Chief Strategy Officer
 - c) Initial notification/ amendment Initial notification

- 2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

- a) Name GlaxoSmithKline plc
- b) LEI 5493000HZTVUYLO1D793

- 3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

Ordinary shares of 25 pence each ('Ordinary Shares')

- a) Description of the financial instrument ISIN: GB0009252882

- b) Nature of the transaction Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 11 October 2018.

- c) Price(s) and volume(s)

Price(s)	Volume(s)
£14.5879	2012.555
n/a (single transaction)	

Aggregated information

- d) Aggregated volume Price

- e) Date of the transaction 2018-10-12
- f) Place of the transaction London Stock Exchange (XLON)

- 1. Details of PDMR/person closely associated with them ('PCA')
 - a) Name Mr R Simard
 - b) Position/status President, Pharma Supply Chain

- c) Initial notification/ amendment Initial notification

- 2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

- a) Name GlaxoSmithKline plc
 b) LEI 5493000HZTVUYLO1D793
 Details of the transaction(s): section to be repeated for (i) each type
 3. of instrument; (ii) each type of transaction; (iii) each date; and (iv)
 each place where transaction(s) has been conducted

Ordinary shares of 25 pence
 each ('Ordinary Shares')

- a) Description of the financial instrument ISIN: GB0009252882

- b) Nature of the transaction Acquisition of Ordinary
 Shares following the
 re-investment of dividends
 paid to shareholders on 11
 October 2018.

- c) Price(s) and volume(s)

Price(s)	Volume(s)
£14.5879	375.703
n/a (single transaction)	

Aggregated information

- d) Aggregated volume Price

- e) Date of the transaction 2018-10-12
 f) Place of the transaction London Stock Exchange
 (XLON)

1. Details of PDMR/person closely associated with them ('PCA')

- a) Name Ms C Thomas
 b) Position/status SVP, Human Resources
 c) Initial notification/
 amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction
 platform, auctioneer or auction monitor

- a) Name GlaxoSmithKline plc
 b) LEI 5493000HZTVUYLO1D793
 Details of the transaction(s): section to be repeated for (i) each type
 3. of instrument; (ii) each type of transaction; (iii) each date; and (iv)
 each place where transaction(s) has been conducted

Ordinary shares of 25 pence
 each ('Ordinary Shares')

- a) Description of the financial instrument ISIN: GB0009252882

- b) Nature of the transaction Acquisition of Ordinary
 Shares following the
 re-investment of dividends
 paid to shareholders on 11
 October 2018.

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

c) Price(s) and volume(s)	Price(s)	Volume(s)
	£14.5879	755.083
	n/a (single transaction)	

Aggregated information

d) Aggregated volume Price

e) Date of the transaction	2018-10-12
f) Place of the transaction	London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')

a) Name	Mr P C Thomson
b) Position/status	President, Global Affairs

c) Initial notification/ amendment	Initial notification
------------------------------------	----------------------

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name	GlaxoSmithKline plc
b) LEI	5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a) Description of the financial instrument	Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
--	--

b) Nature of the transaction	Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 11 October 2018.
------------------------------	--

c) Price(s) and volume(s)	Price(s)	Volume(s)
	£14.5879	217.548
	n/a (single transaction)	

Aggregated information

d) Aggregated volume Price

e) Date of the transaction	2018-10-12
f) Place of the transaction	London Stock Exchange (XLON)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc
(Registrant)

Date: October 16, 2018

By: VICTORIA WHYTE

Victoria Whyte
Authorised Signatory for and on
behalf of GlaxoSmithKline plc